(Q39255848)

10 September 2017

title

Role of Inflammation in Heart Failure (English)

1 reference

10 September 2017

0 references

0 references

Lily F Shirazi

1

1 reference

10 September 2017

Joe Bissett

series ordinal

2

1 reference

10 September 2017

Francesco Romeo

series ordinal

3

1 reference

10 September 2017

Jawahar L Mehta

series ordinal

4

1 reference

10 September 2017

publication date

1 June 2017

1 reference

Current Atherosclerosis Reports

10 September 2017

published in

1 reference

10 September 2017

volume

19

1 reference

10 September 2017

issue

6

1 reference

10 September 2017

page(s)

27

1 reference

Heart failure and the aging population: an increasing burden in the 21st century?

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Basic mechanisms in heart failure: the cytokine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Innate immunity and the failing heart: the cytokine hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Interleukin-1β induces a reversible cardiomyopathy in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Survival pathways in hypertrophy and heart failure: the gp130-STAT axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

The varying faces of IL-6: From cardiac protection to cardiac failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

IL-17A promotes ventricular remodeling after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Profibrotic Role for Interleukin-4 in Cardiac Remodeling and Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Soluble ST2 in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Inflammation in Heart Failure: The Holy Grail?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Macrophages dictate the progression and manifestation of hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Silencing of CCR2 in myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Continuous Glycoprotein-130–Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-017-0660-3

Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha

21 January 2018

1 reference

12 December 2020

Interleukin-17A Is Dispensable for Myocarditis but Essential for the Progression to Dilated Cardiomyopathy

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy

1 reference

12 December 2020

Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure

1 reference

12 December 2020

Study on activity of inflammatory factors in patients with chronic heart failure depending on the stage of the disease and NYHA class

1 reference

12 December 2020

A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy

1 reference

12 December 2020

[Interleukin-4 and cardiac fibrosis in patients with heart failure]

1 reference

12 December 2020

Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects

1 reference

12 December 2020

10.1007/S11883-017-0660-3

Identifiers

DOI

1 reference

10 September 2017

1 reference